STOCK TITAN
  1. Home
  2. News
  3. ICLR

Icon Plc - ICLR STOCK NEWS

Welcome to our dedicated news page for Icon Plc (Ticker: ICLR), a resource for investors and traders seeking the latest updates and insights on Icon Plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Icon Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Icon Plc's position in the market.

News
ICON Announces CFO Transition
Rhea-AI Summary
ICON plc (ICLR) announces Chief Financial Officer's departure for a new opportunity. The company reaffirms its full year 2024 guidance with revenue expected to be $8,400 - $8,800 million and adjusted earnings per share in the range of $14.50 - $15.30.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.46%
Tags
none
-
News
ICON plc Schedules First Quarter 2024 Earnings Conference Call
Rhea-AI Summary
ICON plc (ICLR) to announce first quarter 2024 financial results on April 24, 2024, followed by a conference call on April 25, 2024. Webcast details will be available on the Investor section of the website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.03%
Tags
earnings
-
News
ICON plc to Present at Upcoming Investor Conferences
Rhea-AI Summary
ICON plc (ICLR) CFO and CEO to present at upcoming healthcare conferences in March 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.17%
Tags
conferences
News
ICON Reports Fourth Quarter and Full Year 2023 Results
Rhea-AI Summary
ICON plc (NASDAQ:ICLR) reports strong financial results for the fourth quarter and full year 2023, with net business wins of $2,531 million in the quarter and $9,946 million for the full year. Revenue increased by 5.3% in quarter four to $2,066.2 million, with adjusted EBITDA of $448.2 million. Full-year revenue reached $8,120.2 million, with adjusted EBITDA of $1,694.1 million. GAAP net income for the quarter was $216.4 million, and $612.3 million for the full year. The company reaffirmed its financial guidance for 2024, expecting revenue of $8,400 - $8,800 million and adjusted earnings per share of $14.50 - $15.30.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.07%
Tags
earnings
-
News
ICON plc Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call
Rhea-AI Summary
ICON plc (ICLR) will release its Q4 and full year 2023 financial results on February 21, 2024, followed by a conference call and webcast on February 22, 2024. The company will discuss its performance and provide webcast links on its Investor section. A webcast replay will also be available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
earnings
-
News
New ICON Survey Highlights Importance of Combination Therapies in Future Obesity Treatment
Rhea-AI Summary
ICON plc (ICLR) announced results from a survey of professionals engaged in obesity-related clinical research, revealing a focus on combination therapies and multi-indication studies. The majority of respondents believe future obesity therapies will focus on measuring more than one outcome. 66% of respondents are confident in their obesity-related pipeline success prospects. However, challenges include lack of long-term follow-up studies, obesity-specific trial design, and diverse patient recruitment. The survey highlights the potential for significant advancements in obesity clinical research in the coming years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.09%
Tags
none
News
ICON Issues Financial Guidance for Full Year 2024
Rhea-AI Summary
ICON plc (ICLR) announces full year 2024 revenue guidance of $8,400 - $8,800 million, representing 3.2% – 8.1% growth over Full Year 2023. Adjusted earnings per share1 guidance is in the range of $14.50 - $15.30, representing growth of 13.5% – 19.8% over Full Year 2023. CEO Dr. Steve Cutler comments on the company's strengthened position as a market-leading provider of clinical development services and positive demand environment for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.6%
Tags
none
-
News
Biotech companies to increase R&D spend but highlight complexity of clinical trials - ICON
Rhea-AI Summary
ICON plc (NASDAQ: ICLR) launches 'Optimising biotech funding' whitepaper to provide an overview of the current state of play for biotech companies and the research and development (R&D) strategies they can adopt to attract and best utilize investment funding. A recent survey of over 130 biotech executives shows that 60% of respondents expected to increase R&D spending, while only 2% planned to reduce funding. The survey also highlights the challenges in bringing novel therapies to market and the need for biotechs to consider more comprehensive partnerships with clinical development partners. The whitepaper covers considerations for biotechnology companies pursuing funding from sources such as venture capital firms and partnerships with large pharmaceutical companies, strategic outsourcing decisions, and best practices to optimize trial designs, development timelines, and program value to maximize the impact of funding.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
clinical trial
-
News
ICON plc to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
ICON plc (ICLR) CEO to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.13%
Tags
conferences
News
ICON Wins Industry Accolades from TIME Magazine, Forbes and Financial Times in Second Half of 2023
Rhea-AI Summary
ICON plc (NASDAQ: ICLR) is recognized as a top-rated employer and leader in clinical trial innovation, earning accolades for its ESG efforts, employee satisfaction, and diversity practices. The company ranked 88th in TIME’s list of the World’s Best Companies of 2023 and received recognition on Forbes' World’s Best Employers and World’s Top Companies for Women lists. Additionally, ICON was awarded the Financial Times Leaders in Diversity Award and the Frost & Sullivan Institute’s '2023 Enlightened Growth Leadership Award'. The company's CEO, Steve Cutler, emphasized ICON's commitment to achieving ESG goals and creating an inclusive workplace. Furthermore, ICON's digital innovation, marketing campaigns, and employee contributions were also acknowledged through various industry awards.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.35%
Tags
none
Stock ICLR logo
Icon Plc

Nasdaq:ICLR

ICLR Rankings

#426 Ranked by Market Cap
#950 Ranked by Stock Gains
N/A Ranked by Dividends

ICLR Stock Data

25.24B
81.31M
0.66%
101.49%
1.68%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
Ireland
Dublin 18

About ICLR

icon is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. we specialise in the strategic development, management and analysis of programmes that support clinical development - from compound selection to phase i-iv clinical studies. in a highly fragmented industry, we are one of a small group of organisations with the capability and expertise to conduct clinical trials and development projects on either a local or global basis. we have the operational flexibility to provide development services on a stand-alone basis or as part of an integrated “full service” solution. we are also an 'end-to-end'​ pharmacovigilance service provider and this includes post marketing surveillance activities too.